Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Plus Therapeutics Inc
(NQ:
PSTV
)
1.360
UNCHANGED
Streaming Delayed Price
Updated: 3:58 PM EST, Nov 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Plus Therapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Monday's Intraday Session
September 30, 2024
Via
Benzinga
Dow Tumbles Over 200 Points; Carnival Posts Upbeat Earnings
September 30, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Friday's Intraday Session
September 27, 2024
Via
Benzinga
PSTV Stock Earnings: Plus Therapeutics Misses EPS, Misses Revenue for Q2 2024
August 14, 2024
PSTV stock results show that Plus Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
PSTV Stock Earnings: Plus Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 15, 2024
PSTV stock results show that Plus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Recap: Plus Therapeutics Q4 Earnings
March 05, 2024
Via
Benzinga
Plus Therapeutics Earnings Preview
March 04, 2024
Via
Benzinga
Why Plus Therapeutics Stock Popped Today
November 01, 2023
PLUS THERAPEUTICS, Inc. (NASDAQ: PSTV) shares are trading higher on Wednesday.
Via
Benzinga
Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense
April 22, 2024
Plus Therapeutics will secure $3 million in funding from the Department of Defense for pediatric brain cancer trial expansion.
Via
Benzinga
PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023
March 05, 2024
PSTV stock results show that Plus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Earnings Scheduled For March 5, 2024
March 05, 2024
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.
Via
Benzinga
Earnings Outlook For Plus Therapeutics
October 30, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
November 20, 2023
Via
Benzinga
Insiders Buying Plus Therapeutics And 2 Other Stocks Under $2
November 09, 2023
The Dow Jones closed lower by around 40 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 01, 2023
Gainers
Via
Benzinga
Why Plus Therapeutics Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
November 01, 2023
Gainers
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
November 01, 2023
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers investors will want to keep track of today!
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 31, 2023
Via
Benzinga
Earnings Scheduled For October 31, 2023
October 31, 2023
Companies Reporting Before The Bell • BBVA (NYSE:BBVA) is likely to report earnings for its third quarter. • BP (NYSE:BP) is expected to report quarterly earnings at $1.37 per share on revenue of...
Via
Benzinga
Why Is Liquid Biopsy Firm Biocept Stock Trading Lower Today?
October 16, 2023
Biocept Inc (NASDAQ: BIOC) filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware.
Via
Benzinga
Topics
Bankruptcy
Exposures
Financial
Legal
12 Health Care Stocks Moving In Friday's After-Market Session
September 29, 2023
Via
Benzinga
Plus Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
September 18, 2023
The Dow Jones closed lower by close to 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Avantax Shares Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
September 11, 2023
Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
September 11, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
September 08, 2023
Via
Benzinga
Why Is Cancer Diagnostic Focused Biocept Stock Trading Higher Today?
September 08, 2023
Biocept Inc (NASDAQ: BIOC) shares are trading higher after the company signed a non-exclusive licensing agreement for CNSide with Plus Therapeutics Inc (NASDAQ: PSTV), which expands the comprehensive...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
September 08, 2023
Pre-market stock movers are a hot topic worth checking out on Friday with a look at the biggest winners and losers today!
Via
InvestorPlace
EXCLUSIVE: Cancer Firm Plus Therapeutics Licenses Diagnostic Assay To Detect Central Nervous System Cancers
September 08, 2023
Plus Therapeutics Inc (NASDAQ: PSTV) has expanded its supply agreement with Biocept Inc (NASDAQ: BIOC) by acquiring an option to exclusively license Biocept's CNSide, a cerebrospinal flu
Via
Benzinga
Plus Therapeutics Presents Exciting New Clinical Data At Top Cancer Conference
August 14, 2023
Marc Hedrick, President & CEO of Plus Therapeutics (NASDAQ: PSTV), was a guest on Benzinga’s All-Access.
Via
Benzinga
Earnings Scheduled For August 14, 2023
August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.